The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESMO Asia 2022 | IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma
Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses a trial investigating the efficacy and safety of the novel PD-L1 inhibitor, IMC-001, for patients with relapsed/refractory extranodal NK/T cell lymphoma. IMC-001 is similar to atezolizumab and preliminary data is promising. The overall response rate (ORR) was 60%, with all patients achieving complete response. IMC-001 was also reported to be tolerable, with 4 out of 10 patients delaying or stopping treatment (one due to COVID-19 infection) and the most common adverse events including fatigue and cytopenia. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
